Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06525350 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started2024-07
View on ClinicalTrials.gov ↗
This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of glumetinib Tablets and Docetaxel for Injection（Albumin Bound）(HB1801) in the treatment of MET-overexpressed non-small cell lung cancer (NSCLC); The main purpose of Stage 2 is to evaluate the efficacy of the combination of glumetinib tablets and HB1801 compared to glumetinib tablets monotherapy or docetaxel in the treatment of MET-expressed NSCLC.
Trial Details
NCT Number NCT06525350
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Enrollment 256 participants
Start Date 2024-07
Primary Completion 2026-12-25 (estimated)
Study Completion 2028-06-25 (estimated)
Updated on ClinicalTrials.gov 2024-07-29